Renovorx, INC 10-Q quarterly reports

RenovoRx announces record quarterly revenue and commercial expansion, but faces ongoing challenges with Nasdaq listing compliance and continued net losses.

RenovoRx announces significant revenue acceleration in Q1 2026, driven by increased commercial adoption of its RenovoCath device, while its TIGeR-PaC trial nears enrollment completion.

RenovoRx reported increased revenue from RenovoCath sales in Q3 2025, but faces significant net losses and substantial doubt about its ability to continue as a going concern without additional funding.

RenovoRx, Inc. announced significant revenue growth from RenovoCath sales and positive progress in its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer.

RenovoRx reports its Q1 2025 financial results, highlighting initial revenue generation from RenovoCath commercial sales and progress in its Phase III TIGeR-PaC clinical trial.

RenovoRx has issued a common stock purchase warrant to Medical Murray, its contract manufacturing partner, tied to production milestones, as the company explores commercial opportunities for its RenovoCath device.

RenovoRx reported a net loss of $3.465 million for the first six months of 2024, while also highlighting progress in its clinical trials and exploring new commercial opportunities.

RenovoRx reported a net loss of $1.1 million for the first quarter of 2024, alongside updates on their clinical trial and recent financing activities.